{"id":"NCT02096263","sponsor":"GlaxoSmithKline","briefTitle":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","officialTitle":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-04-16","primaryCompletion":"2015-02-06","completion":"2015-11-13","firstPosted":"2014-03-26","resultsPosted":"2018-08-01","lastUpdate":"2019-11-27"},"enrollment":585,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis","Diphtheria","Haemophilus Influenzae Type b","Tetanus","Acellular Pertussis","Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"Infanrix hexa","otherNames":[]},{"type":"BIOLOGICAL","name":"Pediarix","otherNames":[]},{"type":"BIOLOGICAL","name":"ActHIB","otherNames":[]},{"type":"BIOLOGICAL","name":"Pentacel","otherNames":[]},{"type":"BIOLOGICAL","name":"Engerix-B","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix","otherNames":[]},{"type":"BIOLOGICAL","name":"Hiberix","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevnar13","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix","otherNames":[]}],"arms":[{"label":"Infanrix hexa Group","type":"EXPERIMENTAL"},{"label":"Pediarix Group","type":"ACTIVE_COMPARATOR"},{"label":"Pentacel Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.","primaryOutcome":{"measure":"Antibody Concentrations for Pertussis Toxoid (Anti-PT), Filamentous Hemagglutinin (Anti-FHA) and Pertactin (Anti-PRN).","timeFrame":"At Month 5, one month after the third dose of the primary vaccination.","effectByArm":[{"arm":"Infanrix Hexa Group","deltaMin":43.2,"sd":null},{"arm":"Pediarix Group","deltaMin":48.3,"sd":null},{"arm":"Pentacel Group","deltaMin":24.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":43,"countries":["United States"]},"refs":{"pmids":["30444673"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&amp;parentIdentifier=117119&amp;attachmentIdentifier=f37b4392-6468-49a6-9f43-ebda8ddbc0f1&amp;fileName=gsk-117119-clinical-study-report-redact.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":195},"commonTop":["Irritability","Somnolence","Injection site pain","Decreased appetite","Injection site erythema"]}}